Ferric ammonium citrate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ferric ammonium citrate API 1185-57-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ferric ammonium citrate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ferric ammonium citrate
- Synonyms:
- Ferric ammonium citrate, green
- Cas Number:
- 1185-57-5
- DrugBank number:
- DB09501
- Unique Ingredient Identifier:
- UVP74NG1C5
General Description:
Ferric ammonium citrate is a chemical compound identified by the CAS number 1185-57-5. It is known for its distinct pharmacological properties and applications.
Categories:
Ferric ammonium citrate is categorized under the following therapeutic classes: Amines, Ammonium Compounds, Contrast Media, Iron Compounds, Magnetic Resonance Imaging Contrast Media, Nitrogen Compounds, Onium Compounds, Paramagnetic Contrast Media. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ferric ammonium citrate is a type of Contrast Media
Contrast media, a prominent category in the pharmaceutical API sector, plays a crucial role in medical imaging procedures. These specialized substances enhance the visibility of internal body structures during diagnostic tests such as X-rays, CT scans, and MRIs. By optimizing the contrast between different tissues or organs, contrast media enable healthcare professionals to obtain clearer and more detailed images for accurate diagnosis and treatment planning.
Contrast media can be classified into two main types: iodinated and gadolinium-based. Iodinated contrast agents are commonly used in X-ray and CT examinations, while gadolinium-based agents are employed in MRI scans. Both types are designed to interact with specific imaging technologies and provide contrasting properties to the surrounding tissues.
These pharmaceutical APIs are meticulously developed and undergo rigorous testing to ensure safety and efficacy. They are administered intravenously, orally, or via other routes, depending on the imaging technique and medical requirements. Contrast media are carefully formulated to optimize patient comfort and minimize adverse reactions.
Healthcare providers must consider various factors when selecting contrast media, including the patient's medical history, potential allergies, and the specific imaging procedure. Moreover, ongoing research and technological advancements in contrast media aim to improve image quality, reduce side effects, and enhance patient outcomes.
In summary, contrast media are an essential component of modern medical imaging. Their purpose is to enhance image visibility, aid in accurate diagnosis, and contribute to effective treatment planning. Through continuous advancements and stringent quality control, contrast media continue to play a vital role in improving medical imaging techniques and patient care.
